"Clinically predictive preclinical efficacy testing services at your disposal"


Jussi Halleen - CEO, Pharmatest Services

Pharmatest Services Ltd attends AACR-NCI-EORTC Meeting in Boston

Pharmatest Services Ltd attends the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics that will be held in Boston, MA, USA on November 5 – 9, 2015. Pharmatest presents two scientific poster presentations in the conference.

Pharmatest Services Ltd (Pharmatest) is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics is organized by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organisation for Research and Treatment of Cancer (EORTC).

This year Pharmatest attends the AACR-NCI-EORTC conference with the following two scientific poster presentations:

-     Radium-223 dichloride inhibits tumor growth and tumor-induced bone growth in osteoblastic prostate cancer models (in collaboration with Bayer Healthcare)

-      VAL401 decreases tumor volume in a xenograft model of pancreatic cancer utilizing a novel improved luciferase labelling technique (in collaboration with Valirx Plc)

Pharmatest welcomes everyone to visit our posters. If you would like to schedule a meeting with our representatives during the ASBMR meeting, click here.